The effects of pioglitazone on cerebrovascular resistance in patients with type 2 diabetes mellitus

Jong Suk Park, Min Ho Cho, Kyung Yul Lee, Chul Sik Kim, Hai Jin Kim, Ji Sun Nam, Chul Woo Ahn, Bong Soo Cha, Sung Kil Lim, Kyung Rae Kim, Hyun Chul Lee

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Atherosclerosis is one of the major causes of morbidity and mortality in patients with type 2 diabetes mellitus. Pioglitazone has been reported to have antiatherogenic effects. The aim of this study was to investigate whether pioglitazone affects pulsatility index (PI) of the cerebral arteries and the carotid intima-media thickness in type 2 diabetic patients. A total of 40 type 2 diabetic patients were included in this study. They were divided into 2 groups: the pioglitazone-treated group (pioglitazone 15 mg/d with gliclazide 80-320 mg/d for 12 weeks) and the gliclazide-treated group (gliclazide 80-320 mg/d for 12 weeks). Transcranial Doppler ultrasonography was performed for each cerebral artery, and PI was calculated as (systolic velocity - diastolic velocity)/mean velocity. The pioglitazone treatment significantly increased high-density lipoprotein cholesterol and decreased triglyceride levels and insulin resistance. This study revealed that the change in mean intima-media thickness was not significant in both groups, but the change in PI was significantly decreased with pioglitazone compared to gliclazide. In conclusion, pioglitazone decreased PI and improved cerebrovascular resistance in type 2 diabetic patients.

Original languageEnglish
Pages (from-to)1081-1086
Number of pages6
JournalMetabolism: Clinical and Experimental
Volume56
Issue number8
DOIs
Publication statusPublished - 2007 Aug 1

Fingerprint

pioglitazone
Type 2 Diabetes Mellitus
Gliclazide
Cerebral Arteries
Doppler Transcranial Ultrasonography
Carotid Intima-Media Thickness
HDL Cholesterol
Insulin Resistance
Atherosclerosis
Triglycerides

All Science Journal Classification (ASJC) codes

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

Park, Jong Suk ; Cho, Min Ho ; Lee, Kyung Yul ; Kim, Chul Sik ; Kim, Hai Jin ; Nam, Ji Sun ; Ahn, Chul Woo ; Cha, Bong Soo ; Lim, Sung Kil ; Kim, Kyung Rae ; Lee, Hyun Chul. / The effects of pioglitazone on cerebrovascular resistance in patients with type 2 diabetes mellitus. In: Metabolism: Clinical and Experimental. 2007 ; Vol. 56, No. 8. pp. 1081-1086.
@article{3d4feca57ee44651b39e7f18177004e0,
title = "The effects of pioglitazone on cerebrovascular resistance in patients with type 2 diabetes mellitus",
abstract = "Atherosclerosis is one of the major causes of morbidity and mortality in patients with type 2 diabetes mellitus. Pioglitazone has been reported to have antiatherogenic effects. The aim of this study was to investigate whether pioglitazone affects pulsatility index (PI) of the cerebral arteries and the carotid intima-media thickness in type 2 diabetic patients. A total of 40 type 2 diabetic patients were included in this study. They were divided into 2 groups: the pioglitazone-treated group (pioglitazone 15 mg/d with gliclazide 80-320 mg/d for 12 weeks) and the gliclazide-treated group (gliclazide 80-320 mg/d for 12 weeks). Transcranial Doppler ultrasonography was performed for each cerebral artery, and PI was calculated as (systolic velocity - diastolic velocity)/mean velocity. The pioglitazone treatment significantly increased high-density lipoprotein cholesterol and decreased triglyceride levels and insulin resistance. This study revealed that the change in mean intima-media thickness was not significant in both groups, but the change in PI was significantly decreased with pioglitazone compared to gliclazide. In conclusion, pioglitazone decreased PI and improved cerebrovascular resistance in type 2 diabetic patients.",
author = "Park, {Jong Suk} and Cho, {Min Ho} and Lee, {Kyung Yul} and Kim, {Chul Sik} and Kim, {Hai Jin} and Nam, {Ji Sun} and Ahn, {Chul Woo} and Cha, {Bong Soo} and Lim, {Sung Kil} and Kim, {Kyung Rae} and Lee, {Hyun Chul}",
year = "2007",
month = "8",
day = "1",
doi = "10.1016/j.metabol.2007.03.017",
language = "English",
volume = "56",
pages = "1081--1086",
journal = "Metabolism: Clinical and Experimental",
issn = "0026-0495",
publisher = "W.B. Saunders Ltd",
number = "8",

}

Park, JS, Cho, MH, Lee, KY, Kim, CS, Kim, HJ, Nam, JS, Ahn, CW, Cha, BS, Lim, SK, Kim, KR & Lee, HC 2007, 'The effects of pioglitazone on cerebrovascular resistance in patients with type 2 diabetes mellitus', Metabolism: Clinical and Experimental, vol. 56, no. 8, pp. 1081-1086. https://doi.org/10.1016/j.metabol.2007.03.017

The effects of pioglitazone on cerebrovascular resistance in patients with type 2 diabetes mellitus. / Park, Jong Suk; Cho, Min Ho; Lee, Kyung Yul; Kim, Chul Sik; Kim, Hai Jin; Nam, Ji Sun; Ahn, Chul Woo; Cha, Bong Soo; Lim, Sung Kil; Kim, Kyung Rae; Lee, Hyun Chul.

In: Metabolism: Clinical and Experimental, Vol. 56, No. 8, 01.08.2007, p. 1081-1086.

Research output: Contribution to journalArticle

TY - JOUR

T1 - The effects of pioglitazone on cerebrovascular resistance in patients with type 2 diabetes mellitus

AU - Park, Jong Suk

AU - Cho, Min Ho

AU - Lee, Kyung Yul

AU - Kim, Chul Sik

AU - Kim, Hai Jin

AU - Nam, Ji Sun

AU - Ahn, Chul Woo

AU - Cha, Bong Soo

AU - Lim, Sung Kil

AU - Kim, Kyung Rae

AU - Lee, Hyun Chul

PY - 2007/8/1

Y1 - 2007/8/1

N2 - Atherosclerosis is one of the major causes of morbidity and mortality in patients with type 2 diabetes mellitus. Pioglitazone has been reported to have antiatherogenic effects. The aim of this study was to investigate whether pioglitazone affects pulsatility index (PI) of the cerebral arteries and the carotid intima-media thickness in type 2 diabetic patients. A total of 40 type 2 diabetic patients were included in this study. They were divided into 2 groups: the pioglitazone-treated group (pioglitazone 15 mg/d with gliclazide 80-320 mg/d for 12 weeks) and the gliclazide-treated group (gliclazide 80-320 mg/d for 12 weeks). Transcranial Doppler ultrasonography was performed for each cerebral artery, and PI was calculated as (systolic velocity - diastolic velocity)/mean velocity. The pioglitazone treatment significantly increased high-density lipoprotein cholesterol and decreased triglyceride levels and insulin resistance. This study revealed that the change in mean intima-media thickness was not significant in both groups, but the change in PI was significantly decreased with pioglitazone compared to gliclazide. In conclusion, pioglitazone decreased PI and improved cerebrovascular resistance in type 2 diabetic patients.

AB - Atherosclerosis is one of the major causes of morbidity and mortality in patients with type 2 diabetes mellitus. Pioglitazone has been reported to have antiatherogenic effects. The aim of this study was to investigate whether pioglitazone affects pulsatility index (PI) of the cerebral arteries and the carotid intima-media thickness in type 2 diabetic patients. A total of 40 type 2 diabetic patients were included in this study. They were divided into 2 groups: the pioglitazone-treated group (pioglitazone 15 mg/d with gliclazide 80-320 mg/d for 12 weeks) and the gliclazide-treated group (gliclazide 80-320 mg/d for 12 weeks). Transcranial Doppler ultrasonography was performed for each cerebral artery, and PI was calculated as (systolic velocity - diastolic velocity)/mean velocity. The pioglitazone treatment significantly increased high-density lipoprotein cholesterol and decreased triglyceride levels and insulin resistance. This study revealed that the change in mean intima-media thickness was not significant in both groups, but the change in PI was significantly decreased with pioglitazone compared to gliclazide. In conclusion, pioglitazone decreased PI and improved cerebrovascular resistance in type 2 diabetic patients.

UR - http://www.scopus.com/inward/record.url?scp=34347393871&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34347393871&partnerID=8YFLogxK

U2 - 10.1016/j.metabol.2007.03.017

DO - 10.1016/j.metabol.2007.03.017

M3 - Article

C2 - 17618953

AN - SCOPUS:34347393871

VL - 56

SP - 1081

EP - 1086

JO - Metabolism: Clinical and Experimental

JF - Metabolism: Clinical and Experimental

SN - 0026-0495

IS - 8

ER -